Ironwood Pharmaceuticals (NASDAQ:IRWD) Insider Ronald Silver Sells 127,890 Shares of Stock

Posted by Brenda Bartman on Jul 9th, 2026

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) insider Ronald Silver sold 127,890 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the completion of the transaction, the insider directly owned 313,680 shares in the company, valued at approximately $1,417,833.60. This represents a 28.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ IRWD traded down $0.10 during midday trading on Thursday, hitting $4.67. 3,139,903 shares of the company’s stock traded hands, compared to its average volume of 3,478,902. Ironwood Pharmaceuticals, Inc. has a 1 year low of $0.67 and a 1 year high of $5.78. The stock has a market capitalization of $761.49 million, a price-to-earnings ratio of 7.78 and a beta of 0.20. The firm has a fifty day moving average of $3.87 and a 200 day moving average of $3.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The business had revenue of $106.51 million during the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. On average, equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on IRWD. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 1st. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.23.

View Our Latest Stock Analysis on IRWD

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IRWD. Bank of America Corp DE raised its stake in Ironwood Pharmaceuticals by 248.3% during the third quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock valued at $15,321,000 after purchasing an additional 8,337,672 shares in the last quarter. Millennium Management LLC raised its position in shares of Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after buying an additional 4,140,439 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Ironwood Pharmaceuticals by 144.3% during the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after buying an additional 3,641,762 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,975,939 shares of the biotechnology company’s stock valued at $16,769,000 after acquiring an additional 58,603 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Ironwood Pharmaceuticals by 40.7% in the 4th quarter. Marshall Wace LLP now owns 4,424,002 shares of the biotechnology company’s stock valued at $14,909,000 after acquiring an additional 1,279,863 shares during the last quarter.

About Ironwood Pharmaceuticals

(Get Free Report)

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.